A newly completed analysis from the Tufts Center for the Study of Drug Development shows that from 1980 through 2018, the FDA approved a total of 126 cancer drugs to treat solid and hematologic tumors. A dramatic increase to 27% from the 4% share of the 1980s.
For more findings, click here.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.